Literature DB >> 16675737

Effects of fractalkine receptor variants on common carotid artery intima-media thickness.

Giuseppe D Norata1, Katia Garlaschelli, Manuele Ongari, Sara Raselli, Liliana Grigore, Alberico L Catapano.   

Abstract

BACKGROUND AND
PURPOSE: Fractalkine receptor (CX3CR1) plays a key role during atherogenesis. CX3CR1 has 2 common coding polymorphisms, namely V249I and T280M, that have been associated with interindividual differences in susceptibility to atherosclerosis. In the present study, we investigated the possible association between CX3CR1variants and intima-media thickness (IMT).
METHODS: We genotyped 1256 samples from the Progression of Lesions in the Intima of the Carotid (PLIC) study (a prospective population-based study) for the presence of the V249 and the M280 variants of CX3CR1.
RESULTS: Significantly reduced IMT was observed in subjects with the MM280 genotype (0.57+/-0.12 mm) compared with subjects with the TT (0.65+/-0.14 mm) or the TM (0.65+/-0.13 mm) genotype. No difference in IMT was observed within carrier of the II249, VI249, or VV249 genotype. Subjects with combined genotype VI249/MM280 and II249/MM280 showed a reduced IMT.
CONCLUSIONS: The presence of the M280 polymorphism of the fractalkine receptor is associated with a decreased common carotid artery IMT, whereas the presence of the I249 polymorphism does not play a major role on the progression of carotid atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16675737     DOI: 10.1161/01.STR.0000221803.16897.22

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  17 in total

1.  Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data.

Authors:  Matthias W Lorenz; Joseph F Polak; Maryam Kavousi; Ellisiv B Mathiesen; Henry Völzke; Tomi-Pekka Tuomainen; Dirk Sander; Matthieu Plichart; Alberico L Catapano; Christine M Robertson; Stefan Kiechl; Tatjana Rundek; Moïse Desvarieux; Lars Lind; Caroline Schmid; Pronabesh DasMahapatra; Lu Gao; Kathrin Ziegelbauer; Michiel L Bots; Simon G Thompson
Journal:  Lancet       Date:  2012-04-27       Impact factor: 79.321

2.  Zc3h10 is a novel mitochondrial regulator.

Authors:  Matteo Audano; Silvia Pedretti; Gaia Cermenati; Elisabetta Brioschi; Giuseppe Riccardo Diaferia; Serena Ghisletti; Alessandro Cuomo; Tiziana Bonaldi; Franco Salerno; Marina Mora; Liliana Grigore; Katia Garlaschelli; Andrea Baragetti; Fabrizia Bonacina; Alberico Luigi Catapano; Giuseppe Danilo Norata; Maurizio Crestani; Donatella Caruso; Enrique Saez; Emma De Fabiani; Nico Mitro
Journal:  EMBO Rep       Date:  2018-03-05       Impact factor: 8.807

Review 3.  Regulation of atherogenesis by chemokines and chemokine receptors.

Authors:  Wuzhou Wan; Philip M Murphy
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2012-12-07       Impact factor: 4.291

Review 4.  The fate of monocytes in atherosclerosis.

Authors:  G J Randolph
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

Review 5.  Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis.

Authors:  Emmanuel L Gautier; Claudia Jakubzick; Gwendalyn J Randolph
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-10       Impact factor: 8.311

6.  P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors.

Authors:  Andrea Romagnani; Elsa Rottoli; Emilia Maria Cristina Mazza; Tanja Rezzonico-Jost; Benedetta De Ponte Conti; Michele Proietti; Michela Perotti; Elisa Civanelli; Lisa Perruzza; Alberico L Catapano; Andrea Baragetti; Elena Tenedini; Enrico Tagliafico; Simonetta Falzoni; Francesco Di Virgilio; Giuseppe Danilo Norata; Silvio Bicciato; Fabio Grassi
Journal:  Cancer Res       Date:  2020-07-22       Impact factor: 12.701

7.  Fractalkine receptor polymorphism and chronic tonsillitis.

Authors:  Seda Turkoglu Babakurban; Selim S Erbek; Yunus Kasim Terzi; Fatih Arslan; Feride I Sahin
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-02-05       Impact factor: 2.503

8.  Association between OLR1 K167N SNP and intima media thickness of the common carotid artery in the general population.

Authors:  Irene Marta Predazzi; Giuseppe Danilo Norata; Lucia Vecchione; Katia Garlaschelli; Francesca Amati; Liliana Grigore; Lucia Cutuli; Angela Pirillo; Simona Tramontana; Francesco Romeo; Giuseppe Novelli; Alberico Luigi Catapano
Journal:  PLoS One       Date:  2012-02-09       Impact factor: 3.240

Review 9.  Carotid intima-media thickness progression and risk of vascular events in people with diabetes: results from the PROG-IMT collaboration.

Authors:  Matthias W Lorenz; Jackie F Price; Christine Robertson; Michiel L Bots; Joseph F Polak; Holger Poppert; Maryam Kavousi; Marcus Dörr; Eva Stensland; Pierre Ducimetiere; Kimmo Ronkainen; Stefan Kiechl; Matthias Sitzer; Tatjana Rundek; Lars Lind; Jing Liu; Göran Bergström; Liliana Grigore; Lena Bokemark; Alfonsa Friera; David Yanez; Horst Bickel; M Arfan Ikram; Henry Völzke; Stein Harald Johnsen; Jean Philippe Empana; Tomi-Pekka Tuomainen; Peter Willeit; Helmuth Steinmetz; Moise Desvarieux; Wuxiang Xie; Caroline Schmidt; Giuseppe D Norata; Carmen Suarez; Dirk Sander; Albert Hofman; Ulf Schminke; Ellisiv Mathiesen; Matthieu Plichart; Jussi Kauhanen; Johann Willeit; Ralph L Sacco; Stela McLachlan; Dong Zhao; Björn Fagerberg; Alberico L Catapano; Rafael Gabriel; Oscar H Franco; Alpaslan Bülbül; Frank Scheckenbach; Anja Pflug; Lu Gao; Simon G Thompson
Journal:  Diabetes Care       Date:  2015-07-15       Impact factor: 19.112

10.  -374 T/A RAGE polymorphism is associated with chronic kidney disease progression in subjects affected by nephrocardiovascular disease.

Authors:  Ivano Baragetti; Giuseppe Danilo Norata; Cristina Sarcina; Andrea Baragetti; Francesco Rastelli; Laura Buzzi; Liliana Grigore; Katia Garlaschelli; Claudio Pozzi; Alberico Luigi Catapano
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.